Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

NewBiomed Licenses Vaccine Adjuvant to Walvax

publication date: Jun 4, 2008

NewBiomed PIKA Pte. Ltd. of Singapore licensed adjuvant vaccine technology to Yunnan Walvax Biotech Co. Ltd., who will seek SFDA approval for the technology in a nasal spray vaccine for influenza and then market it in China. NewBiomed is developing the use of the adjuvant with a proprietary therapeutic Hepatitis B vaccine. The firm also expects to license its PIKA adjuvant technology to two other companies, also for China influenza vaccines.  More details...



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital